A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.Elizabeth Ruth Plummer, Udai Banerji, Harriet S. Walter et al.|Journal of Clinical Oncology|2019Cited by 31
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.Udai Banerji, Robert H. Jones, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2019Cited by 20
A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.Adam Sharp, Hendrik‐Tobias Arkenau, Anja Williams et al.|Journal of Clinical Oncology|2022Cited by 12
A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.Debashis Sarker, Sophie Glatt, Udai Banerji et al.|Journal of Clinical Oncology|2022Cited by 2
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.Martijn P. Lolkema, Sarah P. Blagden, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2019Cited by 1